Report forecasts shift in musculoskeletal pain therapeutics market
A new market analysis from DelveInsight highlights a transition in musculoskeletal pain treatment toward non-opioid therapies and regenerative medicine.
A comprehensive market report by DelveInsight examines the evolving landscape for musculoskeletal pain treatments through 2036. The analysis identifies a significant industry shift from standard symptomatic management toward regenerative medicine and disease-modifying osteoarthritis drugs (DMOADs).
Key pharmaceutical developments include Biosplice Therapeutics' NDA submission for its knee osteoarthritis candidate, lorecivivint, and Mesoblast’s advancement of rexlemestrocel-L, which is targeting a 2028 U.S. launch. Additionally, Taiwan Liposome Company is exploring data suggesting that its TLC599 treatment may provide structural benefits for patients with osteoarthritis.
Given that musculoskeletal conditions affect approximately 1.7 billion people globally, these pipeline developments are aimed at addressing patients who have exhausted conservative treatments. The industry's current focus on non-opioid analgesics and specialized injections reflects a broader clinical effort to reduce dependence on invasive surgical interventions and traditional systemic painkillers.